While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...

Delays in diagnosing and treating psoriatic arthritis—a common inflammatory disorder affecting around 200,000 people in the U ...

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...

A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

Learn about different types of eczema, symptoms, treatment options, and how to differentiate from other skin conditions.

The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Almirall has announced that it will be hosting the 16th edition of its Skin Academy, a conference that encourages ...

Journalist working with Al Jazeera killed in Israeli Gaza strike, network says Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16 th edition of Skin Academy, a ...

Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, ...

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...